Xinvento

Amsterdam, Netherlands Founded: 2021 • Age: 5 yrs Acquired By Rhythm Pharmaceuticals
Therapies for congenital hyperinsulinism are researched and developed.

About Xinvento

Xinvento is a Healthcare company based in Amsterdam (Netherlands) founded in 2021 by Sarah Hafith and Piet Wigerinck, and was acquired by Rhythm Pharmaceuticals in February 2023. Therapies for congenital hyperinsulinism are researched and developed. Xinvento offers products and services including CHI Treatment. Its focus areas include Life Sciences, Rare Diseases, Drugs and Endocrine Diseases. Its legal entity is Xinvento BV.

Company details

Xinvento was founded in 2021 and is based in Amsterdam, Netherlands. Focus is placed on the research and development of treatments for congenital hyperinsulinism, a rare disease marked by persistent hypoglycemia. Operations center on advancing therapies within the biotechnology sector to address this condition, with activities conducted primarily in Europe. Key personnel include co-founders Sarah Hafith and Piet Wigerinck.

  • Headquarters Amsterdam, Netherlands
  • Founders Sarah Hafith, Piet Wigerinck
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website xinvento.com
  • Social LinkedIn X
  • Acquired by Rhythm Pharmaceuticals (Feb 2023)
  • Legal Name Xinvento Bv
Operational Areas
Key Metrics

Products & Services of Xinvento

Xinvento offers a comprehensive portfolio of products and services, including CHI Treatment.

CHI Treatment
Therapeutics

Developing alternative treatments to manage congenital hyperinsulinism symptoms effectively.

Funding Insights of Xinvento

  • Total Rounds 1
  • Investors Count 8

All 1 funding rounds of Xinvento with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2022Seed––
Valuation history

9 investors in total: 1 institutional and 8 angel.

Investors in Xinvento

Xinvento has secured backing from 9 investors, including angel investors. Prominent investors backing the company include Rhythm Pharmaceuticals, Ed Kaye and John Maraganore.

All
Angel
InvestorDescriptionFounded YearDomainLocation

Ed Kaye

unknown_5397146c8c7e42039

John Maraganore

unknown_e7c472b4a7e349b1a

David Meeker

Angel investor focusing on Indian startups, limited public data available.
unknown_3e46cdae255f4b37a

James Shannon

Angel investor focusing on Indian startups, tech enthusiast
unknown_52116cdd0fca49578

Daniel de Boer

Angel investor and entrepreneur, founder of Procol, focused on agritech and supply chain.
unknown_444acc65bcd342f79

Dinko Valerio

unknown_a1eaae42908e427db

Onno van de Stolpe

Dutch biotech entrepreneur, angel investor, and founder of Galapagos NV.
unknown_95a84abc6d614243b

Hans Schikan

Dutch biotech leader, angel investor in Indian health startups
unknown_254fc864cd1842f58
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010rhythmtx.comBoston, United States
Premium access

Investor details for Xinvento

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Xinvento

3 people are tracked at Xinvento (3 in leadership).

NameRoleGroup
Sarah Hafith
Co-FounderLeadership
Piet Wigerinck
Co-FounderLeadership
Claudine Van Der Sande
Founding CEOLeadership
Premium access

Complete people profiles for Xinvento

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Xinvento

3 dated milestones of Xinvento across 2 years, from founding to its latest funding, stage changes and deals.

  1. Founded Xinvento is founded.
  2. Funding First funding round.
  3. Exit Acquired by Rhythm Pharmaceuticals.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Xinvento

Premium access

Complete news archive for Xinvento

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Xinvento

Xinvento was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Xinvento is headquartered in Amsterdam, Netherlands.

Xinvento was founded in 2021 and is based in Amsterdam, Netherlands. Focus is placed on the research and development of treatments for congenital hyperinsulinism, a rare disease marked by persistent hypoglycemia. Operations center on advancing therapies within the biotechnology sector to address this condition, with activities conducted primarily in Europe. Key personnel include co-founders Sarah Hafith and Piet Wigerinck.

Xinvento offers CHI Treatment.

Xinvento has 9 investors. Key investors include Rhythm Pharmaceuticals, Ed Kaye, John Maraganore, David Meeker, and James Shannon.

Xinvento operates through Xinvento Bv.

Yes. Xinvento was acquired by Rhythm Pharmaceuticals in February 2023.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available